vs
Apellis Pharmaceuticals, Inc.（APLS）与WORKIVA INC（WK）财务数据对比。点击上方公司名可切换其他公司
WORKIVA INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.2倍（$238.9M vs $199.9M），WORKIVA INC净利率更高（4.9% vs -29.5%，领先34.4%），WORKIVA INC同比增速更快（19.5% vs -5.9%），WORKIVA INC自由现金流更多（$50.7M vs $-14.3M），过去两年WORKIVA INC的营收复合增速更高（16.6% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Workiva Inc.是一家全球知名的SaaS企业，主打云原生关联报告合规平台，支持关联数据调用与报告流程自动化，可广泛应用于财务、会计、风险及合规等多个业务场景，助力企业提升运营效率与合规管理水平。
APLS vs WK — 直观对比
营收规模更大
WK
是对方的1.2倍
$199.9M
营收增速更快
WK
高出25.5%
-5.9%
净利率更高
WK
高出34.4%
-29.5%
自由现金流更多
WK
多$65.0M
$-14.3M
两年增速更快
WK
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $238.9M |
| 净利润 | $-59.0M | $11.8M |
| 毛利率 | — | 80.7% |
| 营业利润率 | -25.6% | 3.3% |
| 净利率 | -29.5% | 4.9% |
| 营收同比 | -5.9% | 19.5% |
| 净利润同比 | -62.2% | 234.0% |
| 每股收益（稀释后） | $-0.40 | $0.21 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSWK
| Q4 25 | $199.9M | $238.9M | ||
| Q3 25 | $458.6M | $224.2M | ||
| Q2 25 | $178.5M | $215.2M | ||
| Q1 25 | $166.8M | $206.3M | ||
| Q4 24 | $212.5M | $199.9M | ||
| Q3 24 | $196.8M | $185.6M | ||
| Q2 24 | $199.7M | $177.5M | ||
| Q1 24 | $172.3M | $175.7M |
净利润APLSWK
| Q4 25 | $-59.0M | $11.8M | ||
| Q3 25 | $215.7M | $2.8M | ||
| Q2 25 | $-42.2M | $-19.4M | ||
| Q1 25 | $-92.2M | $-21.4M | ||
| Q4 24 | $-36.4M | $-8.8M | ||
| Q3 24 | $-57.4M | $-17.0M | ||
| Q2 24 | $-37.7M | $-17.5M | ||
| Q1 24 | $-66.4M | $-11.7M |
毛利率APLSWK
| Q4 25 | — | 80.7% | ||
| Q3 25 | — | 79.3% | ||
| Q2 25 | — | 77.0% | ||
| Q1 25 | — | 76.6% | ||
| Q4 24 | — | 77.1% | ||
| Q3 24 | — | 76.5% | ||
| Q2 24 | — | 76.8% | ||
| Q1 24 | — | 76.4% |
营业利润率APLSWK
| Q4 25 | -25.6% | 3.3% | ||
| Q3 25 | 48.7% | -1.5% | ||
| Q2 25 | -18.6% | -10.3% | ||
| Q1 25 | -50.0% | -12.0% | ||
| Q4 24 | -12.3% | -6.7% | ||
| Q3 24 | -24.0% | -11.7% | ||
| Q2 24 | -14.7% | -13.0% | ||
| Q1 24 | -36.0% | -10.4% |
净利率APLSWK
| Q4 25 | -29.5% | 4.9% | ||
| Q3 25 | 47.0% | 1.2% | ||
| Q2 25 | -23.6% | -9.0% | ||
| Q1 25 | -55.3% | -10.4% | ||
| Q4 24 | -17.1% | -4.4% | ||
| Q3 24 | -29.2% | -9.2% | ||
| Q2 24 | -18.9% | -9.9% | ||
| Q1 24 | -38.5% | -6.7% |
每股收益（稀释后）APLSWK
| Q4 25 | $-0.40 | $0.21 | ||
| Q3 25 | $1.67 | $0.05 | ||
| Q2 25 | $-0.33 | $-0.35 | ||
| Q1 25 | $-0.74 | $-0.38 | ||
| Q4 24 | $-0.30 | $-0.15 | ||
| Q3 24 | $-0.46 | $-0.31 | ||
| Q2 24 | $-0.30 | $-0.32 | ||
| Q1 24 | $-0.54 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $338.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $-5.4M |
| 总资产 | $1.1B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSWK
| Q4 25 | $466.2M | $338.8M | ||
| Q3 25 | $479.2M | $315.9M | ||
| Q2 25 | $370.0M | $284.3M | ||
| Q1 25 | $358.4M | $242.0M | ||
| Q4 24 | $411.3M | $301.8M | ||
| Q3 24 | $396.9M | $248.2M | ||
| Q2 24 | $360.1M | $267.9M | ||
| Q1 24 | $325.9M | $296.1M |
总债务APLSWK
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSWK
| Q4 25 | $370.1M | $-5.4M | ||
| Q3 25 | $401.2M | $-36.9M | ||
| Q2 25 | $156.3M | $-66.5M | ||
| Q1 25 | $164.2M | $-75.7M | ||
| Q4 24 | $228.5M | $-41.7M | ||
| Q3 24 | $237.1M | $-50.8M | ||
| Q2 24 | $264.3M | $-77.7M | ||
| Q1 24 | $266.7M | $-83.2M |
总资产APLSWK
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $821.4M | $1.3B | ||
| Q1 25 | $807.3M | $1.3B | ||
| Q4 24 | $885.1M | $1.4B | ||
| Q3 24 | $901.9M | $1.3B | ||
| Q2 24 | $904.5M | $1.2B | ||
| Q1 24 | $831.9M | $1.2B |
负债/权益比APLSWK
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $51.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $50.7M |
| 自由现金流率自由现金流/营收 | -7.1% | 21.2% |
| 资本支出强度资本支出/营收 | 0.1% | 0.1% |
| 现金转化率经营现金流/净利润 | — | 4.31× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $138.0M |
8季度趋势，按日历期对齐
经营现金流APLSWK
| Q4 25 | $-14.2M | $51.0M | ||
| Q3 25 | $108.5M | $46.2M | ||
| Q2 25 | $4.4M | $50.3M | ||
| Q1 25 | $-53.4M | $-7.4M | ||
| Q4 24 | $19.4M | $44.0M | ||
| Q3 24 | $34.1M | $18.9M | ||
| Q2 24 | $-8.3M | $-14.0K | ||
| Q1 24 | $-133.0M | $24.8M |
自由现金流APLSWK
| Q4 25 | $-14.3M | $50.7M | ||
| Q3 25 | $108.3M | $46.1M | ||
| Q2 25 | $4.4M | $49.3M | ||
| Q1 25 | $-53.4M | $-8.1M | ||
| Q4 24 | $19.3M | $43.2M | ||
| Q3 24 | — | $18.7M | ||
| Q2 24 | $-8.4M | $-122.0K | ||
| Q1 24 | $-133.3M | $24.6M |
自由现金流率APLSWK
| Q4 25 | -7.1% | 21.2% | ||
| Q3 25 | 23.6% | 20.5% | ||
| Q2 25 | 2.5% | 22.9% | ||
| Q1 25 | -32.0% | -3.9% | ||
| Q4 24 | 9.1% | 21.6% | ||
| Q3 24 | — | 10.1% | ||
| Q2 24 | -4.2% | -0.1% | ||
| Q1 24 | -77.3% | 14.0% |
资本支出强度APLSWK
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.5% | ||
| Q1 25 | 0.0% | 0.4% | ||
| Q4 24 | 0.0% | 0.4% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | 0.0% | 0.1% | ||
| Q1 24 | 0.2% | 0.1% |
现金转化率APLSWK
| Q4 25 | — | 4.31× | ||
| Q3 25 | 0.50× | 16.57× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
WK
| License And Service | $219.3M | 92% |
| XBRL Professional Services | $16.4M | 7% |
| Other Services | $3.2M | 1% |
